The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma

Anti-Cancer Drugs

Volumn 11, Issue 10, 2000, Pages 865-871

  Neale, Michael H ^a   Lamont, Alan ^b   Hindley, Andrew ^c   Kurbacher, Christian M ^d   Cree, Ian A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SOUTHEND HOSPITAL   (United Kingdom)

^c ROYAL PRESTON HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ATP; Chemotherapy; Doxorubicin; Gemcitabine; Liposome; Ovarian carcinoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; GEMCITABINE; LIPOSOME;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER INHIBITION; CANCER RECURRENCE; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0033635221     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200011000-00011     Document Type: Article

References (46)

1. Treatment of refractory and recurrent ovarian cancer
2. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer
3. Doxorubicin in sterically stabilized liposomes
4. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
5. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
6. Development of liposomal anthracyclines: From basics to clinical applications
7. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
8. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil)
9. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma
10. Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma
11. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy
12. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial
13. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
14. Clinical studies of liposome-encapsulated doxorubicin
15. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy
16. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
17. Doxil in breast cancer
18. Monotherapy of metastatic breast cancer: A review of newer agents
19. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
20. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: Clinical correlation for cisplatin resistance of ovarian carcinoma
21. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells
22. Luminescence-based cell viability testing
23. Cellular resistance to anthracyclines
24. DNA topoisomerases
25. The role of topoisomerase II in multidrug resistance
26. Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma
27. The role of DNA mismatch repair in drug resistance
28. The significance of the sequence of administration of topotecan and etoposide
29. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line
30. ATP-based tumour chemosensitivity testing: Assisting new agent development
31. Combination chemotherapy for choroidal melanoma: Ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside
32. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic and solid tumors
33. Phase I study of Doxil and vinorelbine in metastatic breast cancer
34. Doxil and oral cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MSDC): Preliminary results of a pilot trial
35. Doxil plus cisplatin: Combined results of two phase I studies
36. Phase II trial to evaluate the safety and tolerability of Caelyx (Doxil) in combination with paclitaxel in the treatment of metastatic cancer
37. Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HCl liposome injection (Doxil) plus paclitaxel (DT) in metastatic breast cancer
38. Phase I trial of liposomal doxorubicin (Doxil) and docetaxel (Taxotere) in patients (pts) with advanced breast cancer (ABC)
39. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer
40. Phase 1 trial of doxil and topotecan in solid tumors
41. Doxorubicin inhibits human DNA topoisomerase I
42. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
43. The Gynecologic Oncology Group experience in ovarian cancer
44. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer
45. A randomised trial of chemotherapy directed by a tumour chemosensitivity assay versus physician's choice in patients with recurrent platinum-resistant ovarian adenocarcinoma
46. Individualizing chemotherapy for solid tumors - Is there any alternative?